LGK-974 is under clinical development by Novartis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LGK-974’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LGK-974 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LGK-974 overview

LGK-974 is under development for the treatment of solid tumor, triple negative breast cancer (first and second), cervical squamous cell cancer, esophageal squamous cell cancer, lung squamous cell cancer, colorectal cancer, melanoma, metastatic triple negative breast cancer, metastatic pancreatic adenocarcinoma, metastatic head, and neck squamous cell cancer. The drug candidate is administered orally. It targets porcupine, a membrane-bound O-acyltransferase enzyme. It was also under development for gastric cancer, metastatic colorectal cancer.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Quick View LGK-974 LOA Data

Report Segments
  • Innovator
Drug Name
  • LGK-974
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.